Rheum Res 2


		Basic & Clinical Research

	For Rheumatoid Arthritis and Osteoarthritis: COX-2 STUDY A Multicenter, Double-Blind, Parallel Group Study Comparing the Incidence of Clinically Significant Upper GI Adverse Events Associated with Celecoxib (SC-58635) 400 mg bid to that of Ibuprofen 800 mg tid in Patients with OA or RA *Opened to any type of OA (hip, knee, spine, shoulder, foot etc.) or RA (RF +/ RF-)*

Inclusion Criteria:

Documented Diagnosis of RA or OA for at least 3 months requiring chronic NSAID use

Must be willing to participate for the duration of the study (52 weeks)

Exclusion Criteria:

No active GI disease

No history of gastric or duodenal surgery other than simple oversew of an ulcer or perforation

NO regular use of anti-ulcer medications (H-2 antagonists, proton pump inhibitors, sucralfate and misoprostol) Short-term use of antacids is permitted.

NO active malignancy (history of malignancy acceptable if no evidence of recurrence in 5 years or greater)

NO hypersensitivity to COX-2 inhibitors, sulfonamides, or ibuprofen

***Patients will be paid $150 for participation***

Contact:
Eileen McCullagh, RN, CCRC
Voicemail: 212-598-6613
Beeper: (917) 218-5449
E-mail: Eileen.McCullagh@Med.NYU.Edu




	Home \| General Information \| Departments \| Programs Conditions We Treat \| Academic & Professional \| Research info@hjdhospital.com employmentopportunities@hjdhospital.com Contact the webmaster@msnyuhealth.org with your comments. ©2000, Hospital for Joint Diseases. All Rights Reserved. Copyright © 2000-2003 Mount Sinai NYU Health